Concepts (178)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antipsychotic Agents | 11 | 2011 | 371 | 1.080 |
Why?
|
| Medicaid | 3 | 2007 | 251 | 0.600 |
Why?
|
| Psychotic Disorders | 6 | 2010 | 146 | 0.530 |
Why?
|
| Anticonvulsants | 2 | 2006 | 362 | 0.380 |
Why?
|
| Platelet Aggregation | 2 | 2000 | 101 | 0.300 |
Why?
|
| Candidiasis | 2 | 2007 | 132 | 0.290 |
Why?
|
| Sodium-Hydrogen Exchangers | 2 | 1999 | 28 | 0.280 |
Why?
|
| Drug Therapy | 1 | 2008 | 84 | 0.280 |
Why?
|
| Antimanic Agents | 1 | 2007 | 33 | 0.260 |
Why?
|
| Fluconazole | 1 | 2007 | 48 | 0.260 |
Why?
|
| Nitric Oxide | 2 | 2000 | 465 | 0.240 |
Why?
|
| Health Resources | 1 | 2007 | 127 | 0.230 |
Why?
|
| Hospitalization | 6 | 2011 | 1933 | 0.230 |
Why?
|
| Schizophrenia | 2 | 2008 | 323 | 0.220 |
Why?
|
| Intensive Care Units | 2 | 2007 | 526 | 0.210 |
Why?
|
| Calcium | 2 | 1999 | 1022 | 0.200 |
Why?
|
| Drug Utilization | 4 | 2010 | 163 | 0.200 |
Why?
|
| Antidepressive Agents | 1 | 2006 | 318 | 0.200 |
Why?
|
| Dementia | 5 | 2010 | 433 | 0.190 |
Why?
|
| Thrombin | 2 | 1999 | 58 | 0.170 |
Why?
|
| Models, Genetic | 2 | 2014 | 748 | 0.170 |
Why?
|
| Computer Simulation | 2 | 2014 | 671 | 0.160 |
Why?
|
| Nursing Homes | 3 | 2010 | 88 | 0.160 |
Why?
|
| Endothelium, Vascular | 2 | 2000 | 467 | 0.160 |
Why?
|
| Lipoproteins, HDL | 1 | 2000 | 97 | 0.150 |
Why?
|
| Software | 2 | 2014 | 731 | 0.140 |
Why?
|
| Aged | 18 | 2011 | 20865 | 0.140 |
Why?
|
| Logistic Models | 6 | 2010 | 1793 | 0.140 |
Why?
|
| Retrospective Studies | 14 | 2011 | 17501 | 0.140 |
Why?
|
| United States | 13 | 2011 | 11872 | 0.130 |
Why?
|
| Aged, 80 and over | 9 | 2011 | 6783 | 0.120 |
Why?
|
| Georgia | 2 | 2006 | 46 | 0.120 |
Why?
|
| Age Factors | 5 | 2011 | 2830 | 0.120 |
Why?
|
| Blood Platelets | 1 | 1998 | 315 | 0.110 |
Why?
|
| Risk | 4 | 2011 | 722 | 0.110 |
Why?
|
| Rabbits | 3 | 2000 | 573 | 0.100 |
Why?
|
| Health Care Surveys | 3 | 2009 | 277 | 0.100 |
Why?
|
| Prescriptions | 2 | 2009 | 44 | 0.090 |
Why?
|
| Residence Characteristics | 3 | 2008 | 291 | 0.090 |
Why?
|
| Socioeconomic Factors | 3 | 2010 | 901 | 0.090 |
Why?
|
| Losartan | 1 | 2011 | 36 | 0.090 |
Why?
|
| Multivariate Analysis | 3 | 2010 | 1376 | 0.090 |
Why?
|
| Activities of Daily Living | 2 | 2010 | 388 | 0.080 |
Why?
|
| Valine | 1 | 2011 | 110 | 0.080 |
Why?
|
| Biphenyl Compounds | 1 | 2011 | 75 | 0.080 |
Why?
|
| Tetrazoles | 1 | 2011 | 71 | 0.080 |
Why?
|
| Benzimidazoles | 1 | 2011 | 155 | 0.080 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2011 | 134 | 0.080 |
Why?
|
| Homes for the Aged | 1 | 2010 | 21 | 0.080 |
Why?
|
| Off-Label Use | 1 | 2010 | 30 | 0.080 |
Why?
|
| Male | 17 | 2011 | 64461 | 0.080 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2011 | 214 | 0.080 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2010 | 37 | 0.080 |
Why?
|
| Cohort Studies | 5 | 2011 | 5039 | 0.080 |
Why?
|
| Female | 18 | 2011 | 70339 | 0.080 |
Why?
|
| Cerebrovascular Disorders | 1 | 2010 | 112 | 0.080 |
Why?
|
| Hematinics | 1 | 2010 | 60 | 0.070 |
Why?
|
| Adult | 8 | 2010 | 31102 | 0.070 |
Why?
|
| Middle Aged | 10 | 2011 | 28371 | 0.070 |
Why?
|
| Accidental Falls | 1 | 2010 | 115 | 0.070 |
Why?
|
| United States Food and Drug Administration | 2 | 2010 | 154 | 0.070 |
Why?
|
| Drug Utilization Review | 1 | 2009 | 26 | 0.070 |
Why?
|
| Sexual Behavior | 1 | 2010 | 231 | 0.070 |
Why?
|
| Humans | 22 | 2013 | 130417 | 0.070 |
Why?
|
| Cattle | 2 | 2000 | 502 | 0.070 |
Why?
|
| Cost-Benefit Analysis | 2 | 2010 | 547 | 0.070 |
Why?
|
| Military Personnel | 1 | 2010 | 210 | 0.070 |
Why?
|
| Heart Failure | 2 | 2011 | 2323 | 0.070 |
Why?
|
| Fractures, Bone | 1 | 2010 | 215 | 0.070 |
Why?
|
| Longitudinal Studies | 2 | 2010 | 1485 | 0.070 |
Why?
|
| Lithium Compounds | 1 | 2007 | 13 | 0.060 |
Why?
|
| Carbamazepine | 1 | 2007 | 40 | 0.060 |
Why?
|
| Drug Resistance, Fungal | 1 | 2007 | 30 | 0.060 |
Why?
|
| Incidence | 3 | 2010 | 3314 | 0.060 |
Why?
|
| Long-Term Care | 1 | 2007 | 70 | 0.060 |
Why?
|
| Lymphoma | 1 | 2010 | 328 | 0.060 |
Why?
|
| Valproic Acid | 1 | 2007 | 140 | 0.060 |
Why?
|
| Drug Labeling | 1 | 2006 | 29 | 0.060 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 644 | 0.060 |
Why?
|
| Affect | 1 | 2007 | 161 | 0.060 |
Why?
|
| Anemia | 1 | 2010 | 351 | 0.060 |
Why?
|
| Health Expenditures | 1 | 2007 | 133 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2007 | 387 | 0.060 |
Why?
|
| Emergency Service, Hospital | 3 | 2010 | 1218 | 0.060 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2008 | 262 | 0.060 |
Why?
|
| Treatment Outcome | 4 | 2011 | 12836 | 0.060 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2006 | 114 | 0.060 |
Why?
|
| Antifungal Agents | 1 | 2007 | 290 | 0.050 |
Why?
|
| Survivors | 1 | 2007 | 345 | 0.050 |
Why?
|
| Vancomycin | 1 | 2006 | 221 | 0.050 |
Why?
|
| Depression | 2 | 2010 | 1313 | 0.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2010 | 915 | 0.050 |
Why?
|
| Surgical Wound Infection | 1 | 2006 | 266 | 0.050 |
Why?
|
| Algorithms | 2 | 2010 | 1663 | 0.050 |
Why?
|
| Risk Factors | 5 | 2011 | 10945 | 0.050 |
Why?
|
| Cross-Sectional Studies | 5 | 2010 | 3795 | 0.050 |
Why?
|
| Drug Prescriptions | 1 | 2005 | 229 | 0.050 |
Why?
|
| Prevalence | 2 | 2008 | 2680 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2007 | 1610 | 0.050 |
Why?
|
| Urban Population | 1 | 2005 | 282 | 0.050 |
Why?
|
| Cross Infection | 1 | 2006 | 333 | 0.050 |
Why?
|
| Bacteremia | 1 | 2006 | 429 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2010 | 877 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2007 | 2088 | 0.040 |
Why?
|
| Mental Disorders | 1 | 2010 | 903 | 0.040 |
Why?
|
| Adolescent | 4 | 2010 | 20724 | 0.040 |
Why?
|
| Length of Stay | 1 | 2007 | 1400 | 0.040 |
Why?
|
| Models, Statistical | 2 | 2014 | 482 | 0.040 |
Why?
|
| Time Factors | 2 | 2010 | 6196 | 0.040 |
Why?
|
| Cardiovascular Diseases | 2 | 2011 | 2099 | 0.040 |
Why?
|
| Nitroarginine | 1 | 1999 | 8 | 0.040 |
Why?
|
| Propensity Score | 2 | 2011 | 272 | 0.040 |
Why?
|
| Nitric Oxide Synthase | 1 | 1999 | 169 | 0.040 |
Why?
|
| HIV Infections | 1 | 2010 | 2029 | 0.030 |
Why?
|
| Nigericin | 1 | 1998 | 2 | 0.030 |
Why?
|
| Egtazic Acid | 1 | 1998 | 17 | 0.030 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 1999 | 185 | 0.030 |
Why?
|
| Biological Transport, Active | 1 | 1998 | 70 | 0.030 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2006 | 1152 | 0.030 |
Why?
|
| Anxiety | 3 | 2009 | 1006 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2011 | 1391 | 0.030 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 1999 | 276 | 0.030 |
Why?
|
| In Vitro Techniques | 1 | 1998 | 809 | 0.030 |
Why?
|
| Aorta | 1 | 2000 | 521 | 0.030 |
Why?
|
| Databases, Factual | 2 | 2011 | 1223 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2006 | 2571 | 0.030 |
Why?
|
| Aorta, Thoracic | 1 | 1999 | 527 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2000 | 2895 | 0.030 |
Why?
|
| Animals | 3 | 2000 | 33847 | 0.020 |
Why?
|
| Models, Structural | 1 | 2011 | 34 | 0.020 |
Why?
|
| Valsartan | 1 | 2011 | 26 | 0.020 |
Why?
|
| Fosinopril | 1 | 2011 | 4 | 0.020 |
Why?
|
| Enalapril | 1 | 2011 | 13 | 0.020 |
Why?
|
| Captopril | 1 | 2011 | 23 | 0.020 |
Why?
|
| Lisinopril | 1 | 2011 | 27 | 0.020 |
Why?
|
| Nigeria | 1 | 2010 | 72 | 0.020 |
Why?
|
| Condoms | 1 | 2010 | 47 | 0.020 |
Why?
|
| Insurance Claim Reporting | 1 | 2010 | 7 | 0.020 |
Why?
|
| Surveys and Questionnaires | 2 | 2010 | 4032 | 0.020 |
Why?
|
| Sexual Partners | 1 | 2010 | 79 | 0.020 |
Why?
|
| Risk-Taking | 1 | 2010 | 94 | 0.020 |
Why?
|
| Internet | 1 | 2013 | 422 | 0.020 |
Why?
|
| Texas | 2 | 2010 | 3642 | 0.020 |
Why?
|
| Evolution, Molecular | 1 | 2013 | 645 | 0.020 |
Why?
|
| Self Efficacy | 1 | 2010 | 205 | 0.020 |
Why?
|
| Child | 2 | 2010 | 26112 | 0.020 |
Why?
|
| Veterans | 2 | 2011 | 1751 | 0.020 |
Why?
|
| Social Class | 1 | 2010 | 210 | 0.020 |
Why?
|
| Social Behavior | 1 | 2010 | 213 | 0.020 |
Why?
|
| Data Collection | 1 | 2010 | 370 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2010 | 451 | 0.020 |
Why?
|
| Quetiapine Fumarate | 1 | 2008 | 14 | 0.020 |
Why?
|
| Dibenzothiazepines | 1 | 2008 | 11 | 0.020 |
Why?
|
| Serotonin Antagonists | 1 | 2008 | 15 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 2899 | 0.020 |
Why?
|
| Health Policy | 1 | 2010 | 225 | 0.020 |
Why?
|
| Risperidone | 1 | 2008 | 59 | 0.020 |
Why?
|
| Benzodiazepines | 1 | 2008 | 105 | 0.020 |
Why?
|
| Hospitals, General | 1 | 2006 | 25 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2011 | 1239 | 0.020 |
Why?
|
| Parenteral Nutrition, Total | 1 | 2006 | 113 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2010 | 1483 | 0.020 |
Why?
|
| Genome, Human | 1 | 2013 | 1314 | 0.010 |
Why?
|
| Sex Factors | 1 | 2009 | 1338 | 0.010 |
Why?
|
| ROC Curve | 1 | 2006 | 610 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2006 | 723 | 0.010 |
Why?
|
| Electronic Health Records | 1 | 2011 | 816 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2006 | 1209 | 0.010 |
Why?
|
| Disease Progression | 1 | 2010 | 2194 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2010 | 3357 | 0.010 |
Why?
|
| Lung Diseases | 1 | 2006 | 396 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 3030 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2010 | 5158 | 0.010 |
Why?
|
| Quality of Life | 1 | 2010 | 2074 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2010 | 1799 | 0.010 |
Why?
|
| Young Adult | 1 | 2010 | 9983 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2006 | 6433 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2010 | 14958 | 0.010 |
Why?
|